2. Signaling Pathways
  3. Neuronal Signaling
  4. α-synuclein

α-synuclein

α-Syn

α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-synuclein regulates synaptic vesicle trafficking and subsequent neurotransmitter release. Genetics and neuropathology studies link α-synuclein to Parkinson's disease (PD) and other neurodegenerative disorders. Accumulation of misfolded oligomers and larger aggregates of α-synuclein defines multiple neurodegenerative diseases called synucleinopathies, but the mechanisms by which α-synuclein acts in neurodegeneration are unknown.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-156585
    CNS-11
    		Inhibitor 98.88%
    CNS-11 is a blood-brain barrier permeable tau fibril-degrading compound. CNS-11 reduces α-synuclein. CNS-11 can be used in Alzheimer's and Parkinson's disease research.
    CNS-11
  • HY-110174
    NAB2
    		Degrader 99.69%
    NAB2 is a neuroprotectant that targets the small GTPase Rab1a. NAB2 selectively binds to the GDP-bound form of Rab1a and protects multiple cell types from α-synuclein toxicity by increasing Rab1a expression. Rab1a regulates ER-to-Golgi trafficking and mediates endosomal trafficking events of the E3 ubiquitin ligase Rsp5/Nedd4. NAB2 stimulates ubiquitination of related proteins in a Nedd4-dependent manner and rescues α-synuclein-associated trafficking defects associated with early-onset Parkinson's disease.
    NAB2
  • HY-125287
    (Rac)-Minzasolmin
    		Inhibitor 99.87%
    (Rac)-Minzasolmin ((Rac)-UCB0599) is a brain penetrating inhibitor of accumulation of alpha-synuclein (ASYN) misfolding and aggregation. (Rac)-Minzasolmin can be used for research of Parkinson's disease.
    (Rac)-Minzasolmin
  • HY-P4704A
    α-Synuclein (61-95) (human) TFA
    α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD).
    α-Synuclein (61-95) (human) TFA
  • HY-145580A
    (S)-Minzasolmin
    		Control
    (S)-Minzasolmin is an isomer of minzasolmin (HY-145580), an inhibitor of α-synuclein oligomerization.
    (S)-Minzasolmin
  • HY-160116
    α-Synuclein aggregate binder 1
    		Inhibitor 98.11%
    α-Synuclein aggregate binder 1 (Compound C05-05) is a collective binder and an inhibitor for α-synuclein aggregation. α-Synuclein aggregate binder 1 is utilized in Positron Emission Tomography (PET) imaging and fluorescence microscope, that can diagnose and ameliorate the neurodegenerative disease.
    α-Synuclein aggregate binder 1
  • HY-P3140A
    α-Synuclein (61-75) TFA
    		99.32%
    α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD).
    α-Synuclein (61-75) TFA
  • HY-115038
    ELN484228
    		Antagonist 99.50%
    ELN484228 is a blocker of α-synuclein which is a key protein in Parkinson’s disease.
    ELN484228
  • HY-163739
    LETC
    		Inhibitor 98.30%
    LETC is an orally active α-synuclein (α-Syn) aggregation inhibitor with an EC50 of 66 nM in transfected DH60.21 neuroblastoma cells. LETC can cross the blood-brain barrier. LETC can be used for the study of synucleinopathies.
    LETC
  • HY-163145
    α-Synuclein inhibitor 11
    		Inhibitor ≥98.0%
    α-Synuclein inhibitor 11 (compound 1) is a selective α-synuclein (α-syn) oligomer formation inhibitor. α-Synuclein inhibitor 11 does not inhibits tau 4R (isoforms 0N4R, 2N4R) or p-tau (isoform 1N4R). α-Synuclein inhibitor 11 can be used for Parkinson's disease (PD) research.
    α-Synuclein inhibitor 11
  • HY-156435
    tau Protein/α-synuclein-IN-1
    		Inhibitor
    tau protein/α-synuclein-IN-1 is a dual inhibitor of tau protein and α-synuclein. tau protein/α-synuclein-IN-1 reduces α-syn inclusions development in M17D neuroblastoma cells. tau protein/α-synuclein-IN-1 can be used in study Alzheimer’s disease.
    tau Protein/α-synuclein-IN-1
  • HY-157308
    α-Synuclein inhibitor 10
    		Inhibitor 99.85%
    α-Synuclein inhibitor 10 (compound a8) inhibits the activity of α-Syn aggregation with low IC50 value (1.08 μM). α-Synuclein inhibitor 10 exhibits good binding affinity to α-Syn residues. α-Synuclein inhibitor 10 can be used in the research of Parkinson's disease (PD).
    α-Synuclein inhibitor 10
  • HY-160831
    PQQ-trimethylester
    		Inhibitor
    PQQ-trimethylester (PQQ-TME) is a synthetic compound that is a trimethylester derivative of pyrroloquinoline quinone (PQQ). PQQ-trimethylester has twice the blood-brain barrier permeability of PQQ (HY-100196) in vitro. In addition, PQQ-trimethylester shows strong inhibitory activity against α-synuclein, amyloid β1-42 (Aβ1-42) and prion protein fibrillation. PQQ-trimethylester can be used in the study of neurodegenerative diseases.
    PQQ-trimethylester
  • HY-N1501R
    Beta-asarone (Standard)
    		Inhibitor
    Beta-asarone (Standard) is the analytical standard of Beta-asarone. This product is intended for research and analytical applications. Beta-asarone is an orally active and BBB-penatrable anti-inflammatory agent and neuroprotective agent, which is the major ingredient of Acorus tatarinowii Schott. Beta-asarone can protect nerve cells from apoptosis and autophagy, inhibit expression of α-synuclein, as well as myocardial protection. Beta-asarone can be used in the study of neurological and cardiovascular diseases.
    Beta-asarone (Standard)
  • HY-120475
    PBT434
    		Inhibitor
    PBT434 is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 has the potential for the research of Parkinson’s disease (PD).
    PBT434
  • HY-121252
    Dopal
    		Inhibitor
    Dopal is an aldehyde that can be generated in Parkinson's disease by enzymatic degradation of dopamine. Dopal can generate reactive oxygen species (ROS), and triggers aggregation of α-synuclein. Dopal elicits α-synuclein accumulation and hampers α-synuclein clearance in primary neurons.
    Dopal
  • HY-P4704
    α-Synuclein (61-95) (human)
    α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD).
    α-Synuclein (61-95) (human)
  • HY-135115
    Oleuropein Aglycone
    		98.46%
    Oleuropein Aglycone (3,4-DHPEA-EA) is a polyphenol and the aglycone form of oleuropein (HY-N0292), formed by enzymatic, acidic or acetylated hydrolysis of oleuropein. Dietary intake of oleuropein Aglycone (50 mg/kg diet) increases the number of neuronal autophagic vesicles, reverses cognitive deficits in the TgCRND8 transgenic mouse model of Alzheimer's disease, and reduces the levels of histone deacetylase 2 (HDAC2) in the cortex and hippocampus. Oleuropein Aglycone increases urinary norepinephrine, interscapular brown adipose tissue epinephrine, and UCP1 protein levels, and reduced plasma leptin levels and total abdominal adipose tissue weight in a rat model of high-fat diet-induced obesity. Oleuropein Aglycone also reduced lung neutrophil infiltration, lipid peroxidation, and IL-1β levels in a mouse model of carrageenan-induced pleurisy.
    Oleuropein Aglycone
  • HY-P5082
    α-Synuclein 4554W
    		Inhibitor 99.53%
    α-Synuclein 4554W is an inhibitor of α-Synuclein (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease.
    α-Synuclein 4554W
  • HY-Y0790R
    Cuminaldehyde (Standard)
    		Inhibitor
    Cuminaldehyde Standard is the analytical standard of Cuminaldehyde. This product is intended for research and analytical applications. Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC50= 0.00085 mg/mL) and α-glucosidase (IC50=0.5 mg/mL). Cuminaldehyde also inhibits the fibrillation of α-synuclein and prevents its aggregation Cuminaldehyde can induce apoptosis in colon adenocarcinoma cells by targeting topoisomerase I and II. In addition, Cuminaldehyde also exerts anti-inflammatory activity by inhibiting lipoxygenase. Cuminaldehyde has a strong inhibitory effect on the growth of Aspergillus flavus and the biosynthesis of aflatoxin B1 (AFB1). Cuminaldehyde can exert anti-injury and anti-neuropathy effects by participating in opioid receptors, L-arginine/NO/cGMP pathways and anti-inflammatory effects. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases.
    Cuminaldehyde (Standard)
Cat. No. Product Name / Synonyms Application Reactivity